Eli Lilly is spending another $3 billion to bulk up manufacturing as the drugmaker seeks to stoke production of some ...
Dan Skovronsky, Eli Lilly Chief Scientific Officer, joins 'Fast Money' to talk Zepbound's recent trial results and what it ...
Eli Lilly said patients taking its obesity drug Zepbound lost 47% more weight than those who were given Novo Nordisk's Wegovy ...
Eli Lilly's popular weight-loss drug Zepbound outperformed Danish drugmaker Novo Nordisk's Wegovy in a clinical trial, ...
Shares of Eli Lilly climbed early Wednesday after the drugmaker detailed a study showing that its blockbuster weight-loss ...
Leerink Partners analyst David Risinger has reiterated their bullish stance on LLY stock, giving a Buy rating on December 2.Don't Miss our ...
Don't Miss our Black Friday Offers: Terence Flynn’s rating is based on the performance and potential of Eli Lilly & Co’s key products, particularly Mounjaro and Zepbound. These medications ...
Eli Lilly’s new products (products launched since 2022 like Ebglyss, Jaypirca, Mounjaro, Kisunla, Omvoh and Zepbound) contributed $4.51 billion to revenues, led by Mounjaro and Zepbound.
While this adds competition to a market currently controlled by Eli Lilly and Novo Nordisk, it also reinforces the dominance of the makers of Wegovy and Zepbound. Amgen reported on Tuesday that ...
Eli Lilly and Company (NYSE: LLY) today announced topline results from the SURMOUNT-5 phase 3b open-label randomized clinical trial. Zepbound® (tirzepatide) provided a 47% greater relative weight ...
Eli Lilly & Company (NYSE:LLY) is a biotechnology company that discovers, develops, and sells human pharmaceuticals. LLY’s main products are Verzenio for cancer, Mounjaro, Zepbound, Jardiance ...
So she asked her doctor about the Eli Lilly drug tirzepatide, which is sold under the brand name Mounjaro to treat diabetes and Zepbound for weight loss. Bonello's workplace insurance plan would ...